The closing price of Moderna Inc (NASDAQ: MRNA) was $98.10 for the day, up 2.66% from the previous closing price of $95.56. In other words, the price has increased by $+2.54 from its previous closing price. On the day, 3315379 shares were traded. MRNA stock price reached its highest trading level at $98.41 during the session, while it also had its lowest trading level at $95.58.
Ratios:
Our analysis of MRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Hoge Stephen sold 309 shares for $94.34 per share. The transaction valued at 29,151 led to the insider holds 1,516,241 shares of the business.
Klinger Shannon Thyme sold 117 shares of MRNA for $11,038 on Mar 04 ’24. The Chief Legal Officer now owns 8,673 shares after completing the transaction at $94.34 per share. On Feb 29 ’24, another insider, Hoge Stephen, who serves as the President of the company, sold 2,388 shares for $94.57 each. As a result, the insider received 225,838 and left with 1,515,898 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 37.48B and an Enterprise Value of 30.12B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.47 while its Price-to-Book (P/B) ratio in mrq is 2.70. Its current Enterprise Value per Revenue stands at 4.46 whereas that against EBITDA is -9.17.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $163.24, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is 98.75, while the 200-Day Moving Average is calculated to be 102.28.
Shares Statistics:
MRNA traded an average of 5.05M shares per day over the past three months and 4.57M shares per day over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 335.35M. Insiders hold about 12.23% of the company’s shares, while institutions hold 66.00% stake in the company. Shares short for MRNA as of Feb 15, 2024 were 24.08M with a Short Ratio of 4.77, compared to 23.07M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.30% and a Short% of Float of 8.38%.
Earnings Estimates
The firm’s stock currently is rated by 12 analysts. On average, analysts expect EPS of -$3.21 for the current quarter, with a high estimate of -$1.94 and a low estimate of -$4.11, while EPS last year was $0.19. The consensus estimate for the next quarter is -$3.32, with high estimates of -$2.04 and low estimates of -$3.94.
Analysts are recommending an EPS of between -$5.83 and -$8.29 for the fiscal current year, implying an average EPS of -$7.1. EPS for the following year is -$4.97, with 18 analysts recommending between -$1.05 and -$7.6.
Revenue Estimates
A total of 19 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $4.73B, while the lowest revenue estimate was $3.69B, resulting in an average revenue estimate of $4.21B. In the same quarter a year ago, actual revenue was $6.85B, down -38.50% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $4.71B in the next fiscal year. The high estimate is $5.88B and the low estimate is $3.23B. The average revenue growth estimate for next year is up 11.90% from the average revenue estimate for this year.
